Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil

Lupus

Volumn 22, Issue 2, 2013, Pages 171-179

  Daleboudt, Gmn ^a   Reinders, Mej ^a   Hartigh, J Den ^a   Huizinga, Twj ^a   Rabelink, A J ^a   De Fijter, J W ^a   Berger, S P ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

AUC; immunosuppression; lupus nephritis; mycophenolate mofetil; pharmacokinetics

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABDOMINAL CRAMP; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84872546074     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312469261     Document Type: Article

References (37)

1. Bihl GR, Petri M, Fine DM. Kidney biopsy in lupus nephritis: Look before you leap. Nephrol Dial Transplant. 2006 ; 21: 1749-1752 (Pubitemid 43985694)
2. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant. 2007 ; 22: 2531-2539 (Pubitemid 47365517)
3. Boumpas DT, Austin HAIII, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992 ; 340: 741-745
4. Petri M. Cyclophosphamide: New approaches for systemic lupus erythematosus. Lupus. 2004 ; 13: 366-371 (Pubitemid 38788498)
5. Flanc RS, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: A meta-analysis of randomized controlled trials. Am J Kidney Dis. 2004 ; 43: 197-208
6. Ioannidis JPA, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000 ; 57: 258-264 (Pubitemid 30227773)
7. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002 ; 46: 2121-2131
8. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010 ; 69: 61-64
9. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 ; 20: 1103-1112
10. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 ; 353: 2219-2228 (Pubitemid 41697285)
11. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 ; 365: 1886-1895
12. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010 ; 69: 2083-2089
13. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999 ; 68: 261-266 (Pubitemid 29360288)
14. Mourad M, Malaise J, Eddour DC, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem. 2001 ; 47: 88-94 (Pubitemid 32064280)
15. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther. 2006 ; 8: R182 - R182
16. van Hest RM, van Gelder T, Vulto AG, Mathot RA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005 ; 44: 1083-1096 (Pubitemid 41356393)
17. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006 ; 28: 145-154 (Pubitemid 44314941)
18. Neumann I, Haidinger M, Jäger H, et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol. 2003 ; 14: 721-727 (Pubitemid 36246016)
19. Roland M, Barbet C, Paintaud G, et al. Mycophenolate mofetil in patients with systemic lupus erythematosus: A prospective pharmacokinetic study. Lupus. 2009 ; 18: 441-447
20. Joy MS, Hilliard T, Hu YC, et al. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy. 2009 ; 29: 7-16
21. Lertdumrongluk P, Somparn P, Kittanamongkolchai W, Traitanon O, Vadcharavivad S, Avihingsanon Y. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int. 2010 ; 78: 389-395
22. Neumann I, Fuhrmann H, Fang IF, Jaeger A, Bayer P, Kovarik J. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant. 2008 ; 23: 3514-3520
23. de Winter BC, van Gelder T. Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases. Nephrol Dial Transplant. 2008 ; 23: 3386-3388
24. Zahr N, Arnaud L, Marquet P, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 2010 ; 62: 2047-2054
25. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277 (Pubitemid 13221242)
26. Cremers S, Schoemaker R, Scholten E, et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol. 2005 ; 60: 249-256 (Pubitemid 41224132)
27. Chan TM, Tse KC, Tang CSO, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005 ; 16: 1076-1084
28. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: The ALMS study. Rheumatology. 2010 ; 49: 128-140
29. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004 ; 350: 971-980 (Pubitemid 38269274)
30. van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006 ; 17: 871-880
31. Zahr N, Amoura Z, Debord J, et al. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet. 2008 ; 47: 277-284 (Pubitemid 351367437)
32. de Winter BC, Neumann I, van Hest RM, van Gelder T, Mathot RA. Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. Ther Drug Monit. 2009 ; 31: 382-390
33. Hood KA, Zarembski DG. Mycophenolate mofetil: A unique immunosuppressive agent. Am J Health Syst Pharm. 1997 ; 54: 285-294 (Pubitemid 27066433)
34. Sagcal-Gironella AC, Fukuda T, Wiers K, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2011 ; 40: 307-313
35. Glander P, Hambach P, Liefeldt L, Budde K. Inosine 5'-monophosphate dehydrogenase activity as a biomarker in the field of transplantation. Clin Chim Acta. 2012 ; 413: 1391-1397
36. Mino Y, Naito T, Matushita T, et al. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. Ther Drug Monit. 2008 ; 30: 656-661
37. Hesselink DA, van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther. 2005 ; 78: 317-321 (Pubitemid 41393666)